KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Deferred Taxes (2021 - 2023)

Historic Deferred Taxes for Moderna (MRNA) over the last 3 years, with Q4 2023 value amounting to -$33.0 million.

  • Moderna's Deferred Taxes rose 6857.14% to -$33.0 million in Q4 2023 from the same period last year, while for Sep 2024 it was -$33.0 million, marking a year-over-year decrease of 10398.07%. This contributed to the annual value of $901.0 million for FY2023, which is 25588.24% up from last year.
  • As of Q4 2023, Moderna's Deferred Taxes stood at -$33.0 million, which was up 6857.14% from $1.5 billion recorded in Q3 2023.
  • Moderna's 5-year Deferred Taxes high stood at $1.5 billion for Q3 2023, and its period low was -$310.0 million during Q1 2023.
  • Over the past 3 years, Moderna's median Deferred Taxes value was -$101.0 million (recorded in 2022), while the average stood at $416666.7.
  • As far as peak fluctuations go, Moderna's Deferred Taxes tumbled by 94545.45% in 2022, and later soared by 160927.84% in 2023.
  • Moderna's Deferred Taxes (Quarter) stood at -$229.0 million in 2021, then surged by 54.15% to -$105.0 million in 2022, then soared by 68.57% to -$33.0 million in 2023.
  • Its last three reported values are -$33.0 million in Q4 2023, $1.5 billion for Q3 2023, and -$220.0 million during Q2 2023.